Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | PTGIR | P43119 | 9/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612311 | 0.81 | HTR1D (0.56) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL8022622 | 0.77 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL8024286 | 0.76 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5438278 | 0.73 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL21497072 | 0.73 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL30617426 | 0.73 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11156319 | 0.72 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6054561 | 0.71 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11160828 | 0.71 | PTGIR (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11162465 | 0.70 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRA2A 7/4885ADRA2B 4/4885ADRA2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.